SCHEMBL649674

SCHEMBL649674

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1ccc2[nH]ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
ALDH1A1 P00352 3/20 0.34
HTT P42858 1/20 0.34
TSHR P16473 2/20 0.32
BCHE P06276 2/20 0.32
KLKB1 P03952 1/20 0.32
GRM2 Q14416 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HPGD P15428 1/20 0.31
HSD17B10 Q99714 1/20 0.31
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
LMNA P02545 1/20 0.30
DRD2 P14416 1/20 0.30
DRD3 P35462 1/20 0.30
DAGLA Q9Y4D2 1/20 0.30
ATP4A P20648 1/20 0.30
ATP4B P51164 1/20 0.30
BACE1 P56817 1/20 0.30
CACNA2D1 P54289 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651784 0.90 C5AR1 (0.46) C5AR1ALDH1A1TSHRBCHEKLKB1
SCHEMBL651033 0.89 C5AR1 (0.44) C5AR1ALDH1A1HTTTSHRKDM4E
SCHEMBL651956 0.88 C5AR1 (0.43) C5AR1ALDH1A1HTTTSHRBCHE
SCHEMBL648790 0.87 C5AR1 (0.43) C5AR1ALDH1A1HTTTSHRBCHE
SCHEMBL650365 0.86 C5AR1 (0.45) C5AR1ALDH1A1TSHRBCHEKLKB1
SCHEMBL5135971 0.86 C5AR1 (0.41) C5AR1ALDH1A1HTTTSHRBCHE
SCHEMBL650580 0.86 C5AR1 (0.41) C5AR1ALDH1A1HTTTSHRKDM4E
SCHEMBL652505 0.86 C5AR1 (0.42) C5AR1ALDH1A1HTTTSHRKDM4E
SCHEMBL648409 0.85 C5AR1 (0.42) C5AR1ALDH1A1HTTTSHRBCHE
SCHEMBL649675 0.85 C5AR1 (0.42) C5AR1ALDH1A1HTTTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed